Zimmer L, McDade C, Beyhaghi H, Purser M, Textoris J, Krause A, Blanc E, Pavlov V, Earnshaw S. Cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury in the French healthcare setting. J Neurotrauma. 2023 Apr;40(7-8):706-19. doi: 10.1089/neu.2022.0270
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Meyers JL, Parasuraman S, Bell K, Graham JP, Candrilli SD. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health. 2014 Feb 27;72(1):6.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Fenton M, Huang H, Hong Y, Hawe E, Kurz DJ, Erusalimsky JD. Early atherogenesis in senescence-accelerated mice. Exp Gerontol. 2004;39(1):115-22.